News

Kingsview Wealth Management recently bought a new stake in Vertex Pharmaceuticals. They snagged 545 shares, valued around ...
For the third summer in a row, Vertex Pharmaceuticals brought its commitment to community and STEM education to life through ...
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...
Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...
Vertex Pharmaceuticals, under the leadership of CEO Reshma Kewalramani, was named in the “Impact Awards” category, which spotlights five standout companies making meaningful advancements in their ...
Proteus Syndrome Market Insight, Epidemiology and Market Forecast - 2034The Proteus Syndrome market is entering a pivotal decade, driven by ...
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $476.95, signifying a +1.45% move from its prior day's close.
Opinion
Zacks Investment Research on MSN1dOpinion

Top Stock Reports for Wells Fargo, Abbott & American Express

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo & Co. (WFC), Abbott ...
Vertex Pharmaceuticals (VRTX) received a significant boost as Health Canada's approval of ALYFTREK marked a vital step in expanding cystic fibrosis treatment options. This approval and other successes ...
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Vertex Pharmaceuticals has solidified its leadership in the cystic fibrosis (CF) market through strategic innovation and ...